Accessibility Menu
Ascentage Pharma Group International logo

Ascentage Pharma Group International(NASDAQ) AAPG

Current Price$18.29
Market Cap$1.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+5%
5 YearN/A
1 Year-54%
1 Month+7%
Ascentage Pharma Group International last closing stock price
MetricPriceDate
Last closeUSD 18.292026-07-24
Ascentage Pharma Group International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.4%USD 18.742026-07-17
1 month+7.08%USD 17.082026-06-24
3 month-23.63%USD 23.952026-04-24
Year to date-30.3%USD 26.242025-12-31
1 year-54%USD 39.762025-07-24
Since inception+5.24%USD 17.382025-01-24

Ascentage Pharma Group International Financials at a Glance

Market Cap

$1.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥1.55B

Net Income (TTM)

-CN¥1.64B

EPS (TTM)

-$1.94

P/E Ratio

-9.42

Dividend

$0.00

Beta (Volatility)

0.87 (Low)

Price

$18.29

Volume

4,578.948

Open

$17.97

Previous Close

$18.29

Daily Range

$17.97 - $18.66

52-Week Range

$16.36 - $48.45

Estimated Earnings Date

Aug 26, 2026

AAPG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ascentage Pharma Group International

Ascentage Pharma Group International is a biotechnology firm based in Suzhou, China, focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for various medical conditions, including cancers and chronic hepatitis B virus infections.

Products and Services
  • HQP1351: A BCR-ABL inhibitor targeting BCR-ABL1 mutants
  • APG-2575: An orally administered Bcl-2 inhibitor for hematologic malignancies
  • APG-115: An oral small molecule targeting MDM2-p53 interactions
Growth Outlook
  • Strong pipeline with multiple candidates in clinical trials
  • Strategic partnerships enhancing research and development capabilities
  • Focus on oncology and chronic diseases aligns with market demand
Financial Highlights
  • Recent quarterly revenue of 334 million CNY, showing growth potential
  • Trailing twelve months (TTM) gross profit margin at 84.09%
  • Cash and cash equivalents of 2.47 billion CNY, providing operational flexibility
Ascentage Pharma Group International is positioned in a rapidly evolving biotechnology sector, with a robust pipeline of innovative therapies targeting significant health challenges. The company's focus on oncology and chronic diseases aligns with increasing global healthcare needs, potentially driving future growth. Recent financial data indicates a solid gross profit margin, reflecting effective cost management and operational efficiency. The substantial cash reserves provide a buffer for ongoing research and development, enabling the company to navigate the complexities of the biotechnology landscape. Overall, Ascentage Pharma presents an intriguing opportunity for investors interested in the biotechnology sector.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

767

CEO

Da Jan Yang, MD, PhD

Website

www.ascentage.com

Headquarters

Suzhou, JS 215000, CN

AAPG Financials

Key Financial Metrics (TTM)

Gross Margin

84.09%

Operating Margin

-210.42%

Net Income Margin

-216.74%

Return on Equity

-123.61%

Return on Capital

-35.66%

Return on Assets

-31.03%

Earnings Yield

-10.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

93.00M

Volume

4.58K

Avg. Volume

11.34K

Financials (TTM)

Gross Profit

CN¥1.43B

Operating Income

-CN¥1.57B

EBITDA

-CN¥1.41B

Operating Cash Flow

-CN¥1.32B

Capital Expenditure

-CN¥52.07M

Free Cash Flow

-CN¥1.38B

Cash & ST Invst.

CN¥2.47B

Total Debt

CN¥1.98B

Ascentage Pharma Group International Performance Analysis

Ascentage Pharma Group International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 31,143,438619.7%
20232023-12-31CNY 31,331,4190.6%
20242024-12-31CNY 136,261,617334.9%
20252025-12-31CNY 79,867,030-41.4%
Ascentage Pharma Group International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30939.0%
Q42024-12-31-81.0%
Q22025-06-3048.9%
Q42025-12-3143.0%
Ascentage Pharma Group International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -1.994.4%
20232023-12-31CNY -1.85-6.9%
20242024-12-31CNY -0.75-59.7%
20252025-12-31CNY -1.94160.3%
Ascentage Pharma Group International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30130.6%
Q42024-12-31-430.9%
Q22025-06-304.9%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥334.13M

+321.4%

Gross Profit

CN¥265.45M

+296.8%

Gross Margin

79.44%

N/A

Market Cap

$1.70BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.22M

N/A

Employees

767

N/A

Net Income

-CN¥639.96M

-22.3%

EBITDA

-CN¥598.95M

-21.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥2.47B

+131.1%

Total Debt

CN¥1.98B

+10.3%

Accounts Receivable

CN¥253.10M

+54.8%

Inventory

CN¥28.64M

+77.1%

Long Term Debt

CN¥757.72M

-35.7%

Short Term Debt

CN¥1.22B

+98.5%

Return on Assets

-31.03%

N/A

Return on Invested Capital

-51.46%

N/A

Free Cash Flow

-CN¥787.41M

-113.0%

Operating Cash Flow

-CN¥779.66M

-118.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZLABZai Lab Limited
$19.22-2.34%
RAREUltragenyx Pharmaceutical Inc.
$26.90-0.44%
SLNOSoleno Therapeutics, Inc.
$53.01+0.00%
IRONDisc Medicine, Inc.
$74.12-2.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About AAPG

What is the current price of Ascentage Pharma Group International?

Ascentage Pharma Group International is trading at $18.29 per share.

What is the 52-week range for Ascentage Pharma Group International?

Over the past 52 weeks, Ascentage Pharma Group International has traded between $16.36 and $48.45.

How much debt does Ascentage Pharma Group International have?

As of the most recent reporting period, Ascentage Pharma Group International reported total debt of CN¥284.49M.

How much cash does Ascentage Pharma Group International have on hand?

Ascentage Pharma Group International reported CN¥171.93M in cash and cash equivalents in its most recent financial results.

What is Ascentage Pharma Group International’s dividend yield?

Ascentage Pharma Group International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services